Cigna Q2 adjusted revenue beats, lifts FY profit forecast on healthcare segment strength
Reuters2026/07/30 10:15
Overview
US health insurer's Q2 adjusted revenue beat analyst expectations, rising 7% yr/yr
Adjusted income from operations rose 6% yr/yr, driven by Cigna Healthcare growth
Company raised 2026 outlook for adjusted income from operations per share
Outlook
Cigna raises 2026 outlook for adj income from operations to at least $30.45 per share
Company expects Evernorth 2026 adj income from operations, pre-tax, at least $6,900 mln
Cigna Healthcare 2026 medical care ratio projected at 83.7% to 84.7%
Result Drivers
HEALTHCARE SEGMENT GROWTH - Cigna said Q2 adjusted income from operations rose due to higher contributions from Cigna Healthcare, including improved margin in U.S. Employer business
PREMIUM RATE INCREASES - Co said higher Cigna Healthcare revenue was primarily due to premium rate increases to cover expected medical cost increases
SPECIALTY VOLUME GROWTH - Co said Specialty and Care Services revenue and profit rose on strong specialty volume growth and higher generic and biosimilar adoption
Company press release: ID:nPn8DLCr3a
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Revenue |
|
$71.67 bln |
|
Q2 Adjusted Revenue |
Beat |
$71.56 bln |
$70.34 bln (18 Analysts) |
Q2 EPS |
|
$6.29 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the managed healthcare peer group is "buy"
Wall Street's median 12-month price target for Cigna Group is $340.00, about 14.7% above its July 29 closing price of $296.47
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago
Reuters Recommended Reads
July 29 - Humana leaves annual adjusted profit outlook unchanged, shares drop
July 28 - Trump administration to end Medicare premium subsidy program
July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OpenAI and Anthropic Want What SpaceX Got After Its IPO Despite Billions in Losses
F5 opens registration for on-demand Post-Mythos Security Summit
GOP Properties insider-linked Ortiz Construcciones sells shares worth EUR 999,990
--Ladenburg Thalmann Initiates Coverage on Evolv Technologies With Buy Rating, $8 Price Target